Brought to you by 
Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned
26 Apr 2021
Executive Summary
Takeda Pharmaceutical Co. Ltd. has licensed exclusive rights to sell AMAG Pharmaceuticals Inc.'s (anemia, cardiovascular, and oncology) intravenous Feraheme (ferumoxytol) for all indications in Europe, Canada, India, Turkey, the Commonwealth of Independent States, and Asia Pacific countries excluding China (where 3SBio already has rights), Japan, and Taiwan.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice